← Back to Search

Dietary Supplement

Endocalyx Pro for Vascular Function in Aging (RESTORE Trial)

N/A

Waitlist Available

Led By Gary Pierce, PhD

Research Sponsored by University of Iowa

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 12 weeks

Awards & highlights

RESTORE Trial Summary

This trial will test if 12-weeks of Endocalyx Pro supplementation can restore the glycocalyx, a thin coating that lines blood vessels, and improve blood vessel function in older adults.

Who is the study for?

This trial is for post-menopausal women aged 60-85 who can fast overnight and pause certain medications. They must be able to lie down comfortably for up to 90 minutes and sign a consent form. Exclusions include those with cardiovascular disease, neurological disorders, severe psychiatric conditions, high blood pressure, obesity (BMI > 40), allergies to specific foods, recent tobacco use, diabetes, major organ diseases or failure, current cancer treatment, autoimmune diseases like lupus or rheumatoid arthritis.Check my eligibility

What is being tested?

The study tests if Endocalyx Pro improves vascular function in older adults by restoring glycocalyx thickness—a key factor in blood vessel health. Over 12 weeks participants take this supplement while researchers measure changes using under-the-tongue imaging and ultrasound of arteries.See study design

What are the potential side effects?

Potential side effects are not detailed here but could relate to the ingredients in Endocalyx Pro which includes olive extract among others; allergic reactions may occur especially in individuals sensitive to olives, artichokes grapes or melons.

RESTORE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Brachial artery flow-mediated dilation (FMD)

Perfused boundary region (PBR)

RESTORE Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Endocalyx ProActive Control1 Intervention

Subjects will receive 6 capsules per day (3,712mg) of Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572), a commercially available supplement that includes a proprietary blend of glycocalyx precursors and antioxidants

Group II: PlaceboPlacebo Group1 Intervention

Subjects will ingest placebo pills

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of IowaLead Sponsor

446 Previous Clinical Trials

879,478 Total Patients Enrolled

3 Trials studying Aging

10,592 Patients Enrolled for Aging

Gary Pierce, PhDPrincipal InvestigatorUniversity of Iowa

2 Previous Clinical Trials

131 Total Patients Enrolled

1 Trials studying Aging

53 Patients Enrolled for Aging

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research initiative permit participants younger than 35 years old?

"The requirements for enrolment in this study dictate that the participants must be between 60 and 85 years of age."

Answered by AI

What types of individuals are ideal participants for this research trial?

"The required age range for enrolment is between 60 and 85 years old, with 24 participants expected to take part."

Answered by AI

What is the current enrollment size for this clinical trial?

"Affirmative. Clinicaltrials.gov displays that this clinical trial is still in need of participants, and began accepting applications on October 10th 2022. The study requires 24 patients from a single medical centre, with new updates released as recently as October 1st 2023."

Answered by AI

Is the opportunity for enrollment in this trial still available to potential participants?

"Affirmative. Clinicaltrials.gov corroborates that this clinical trial, which was first listed on October 10th 2022, is actively recruiting participants. 24 patients must be enrolled from 1 medical site to complete the study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Restoring Glycocalyx Thickness in Older Adults to Improve Vascular Function

Gary L. Pierce, PhD 2022. "Restoring Glycocalyx Thickness in Older Adults to Improve Vascular Function". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06071728.